Alle Storys
Folgen
Keine Story von Intercell AG mehr verpassen.

Intercell AG

EANS-News: Intercell Recognized by U.S. Department of Defense for Development of Japanese Encephalitis Vaccine, IXIARO®

Vienna (Austria)/Washington (USA), May 25, 2010 (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information
Intercell AG (VSE: ICLL) has been honored in a ceremony at the 
Pentagon today for the company´s role in the development of Japanese 
encephalitis vaccine, IXIARO®. The Commanding General, United States 
Army Medical Research and Materiel Command (USAMRMC), the Acting 
Secretary of Defense for Health Affairs (HA) and Gerd Zettlmeissl, 
chief executive officer of Intercell, commented on the excellent 
collaborative efforts between the Department of Defense (DoD) and 
Intercell that lead to the development and subsequent 
commercialization for IXIARO. Senior DoD officials also expressed 
their appreciation to Intercell for making a next-generation JE 
vaccine available for use by Service members. As a result of this 
public-private effort, military personnel, dependants, and civilian 
travelers will be protected against the serious and growing risk of 
disease caused by the JE virus when deployed or traveling to many 
countries of the world.
Gerd Zettlmeissl commented, "We are extremely honored to be 
recognized by the DoD for our collaborative research and development 
efforts. Special recognition is given to our colleagues at Walter 
Reed Army Institute of Research (WRAIR) who initiated this JE vaccine
project in the mid 1990s and contributed to numerous aspects of the 
development program up to licensure."
IXIARO was developed under a Collaborative Research and Development 
Agreement (CRADA) with WRAIR and approved in March 2009 by the U.S. 
Food and Drug Administration for the prevention of Japanese 
Encephalitis. Intercell currently distributes and markets IXIARO to 
the U.S. military, with Novartis Vaccines USA marketing and 
distributing the vaccine to the private market in the U.S.
Japanese Encephalitis is a mosquito-borne infection that strikes 
approximately 50,000 persons per year and is most common in 
developing countries in Asia, including India and China.
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG